ASCO GU 2020: Study EV-103: Preliminary Durability Results of Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
ASCO GU 2020, update on EV-103, patients with metastatic UC who progressed on immunotherapy were given Enfortumab
www.urotoday.com